Patents Examined by Scott Long
  • Patent number: 11503812
    Abstract: Genetically modified mice and methods and compositions for making and using the same are provided, wherein the genetic modification comprises humanization of an Fc?RI protein.
    Type: Grant
    Filed: December 20, 2019
    Date of Patent: November 22, 2022
    Assignee: Regeneron Pharmaceuticals, Inc.
    Inventors: Andrew J. Murphy, Lynn Macdonald, Cagan Gurer, Karolina A. Meagher, Naxin Tu
  • Patent number: 11504427
    Abstract: In alternative embodiments, provided are compositions, including products of manufacture and kits, and methods, for remotely-controlled and non-invasive manipulation of intracellular nucleic acid expression, genetic processes, function and activity in live cells, e.g., adding functions or changing or adding specificities for immune cells, for monitoring physiologic processes, for the correction of pathological processes and for control of therapeutic outcomes. In alternative embodiments, provided are ultrasound-based thermal or mechanical stimulations, and thermo- or mechano-sensitive protein, either synthetically engineered or natively (endogenously) occurring, integrated to control the production of intracellular nucleic acid and gene expression, e.g., for the expression of biological-active proteins, which can be used, in alternative embodiments, for diagnostic or therapeutic purposes.
    Type: Grant
    Filed: November 22, 2017
    Date of Patent: November 22, 2022
    Assignee: The Regents of the University of California
    Inventors: Yingxiao Wang, Shu Chien, Yijia Pan, Yiqian Wu, Shaoying Lu, Kirk Shung
  • Patent number: 11505782
    Abstract: Provided herein are carrier cells and virus combinations and methods for treatment of cancers. Also provided are modified carrier cells for such treatment, and methods of selecting carrier cells that are matched to subjects for such treatment.
    Type: Grant
    Filed: August 8, 2019
    Date of Patent: November 22, 2022
    Assignee: Calidi Biotherapeutics, Inc.
    Inventors: Dobrin Draganov, Aladar A. Szalay
  • Patent number: 11498956
    Abstract: The present application provides inter alia a fusion protein comprising a polypeptide wherein the polypeptide consists of a fragment of invariant chain which is operably linked to an antigenic sequence and wherein the fragment of invariant chain consists of a portion of residues 17-97 of SEQ ID NO: 1, wherein the portion comprises at least 5 contiguous residues from residues 77-92 of SEQ ID NO: 1.
    Type: Grant
    Filed: August 23, 2017
    Date of Patent: November 15, 2022
    Assignees: GLAXOSMITHKLINE BIOLOGICALS SA, UNIVERSITY OF COPENHAGEN
    Inventors: Maria Rosaria Bassi, Riccardo Cortese, Anna Morena D'Alise, Antonella Folgori, Peter Johannes Holst, Alfredo Nicosia
  • Patent number: 11485959
    Abstract: The present invention provides PiggyBac transposase proteins, nucleic acids encoding the same, compositions comprising the same, kits comprising the same, non-human transgenic animals comprising the same, and methods of using the same.
    Type: Grant
    Filed: March 19, 2019
    Date of Patent: November 1, 2022
    Assignee: Poseida Therapeutics, Inc.
    Inventors: Eric M. Ostertag, Blair Madison
  • Patent number: 11472858
    Abstract: Provided are a chimeric antigen receptor targeting CD20 antigen and a preparation method thereof. The extracellular antigen binding domain of the chimeric antigen receptor includes an antibody heavy chain variable region shown in SEQ ID NO: 7 or 9 or 33 and an antibody light chain variable region shown in SEQ ID NO: 11 or 13 or 35, and is capable of killing tumor cells.
    Type: Grant
    Filed: June 21, 2021
    Date of Patent: October 18, 2022
    Assignee: CELLULAR BIOMEDICINE GROUP HK LIMITED
    Inventors: Yihong Yao, Jiaqi Huang, Shigui Zhu, Wei Zhu, Xin Yao, Zhiyuan Li, Li Zhang, Lin Zhu, Anyun Ma, Yutian Wei, Yanfeng Li, Qingxia Wang, Jiaping He
  • Patent number: 11464805
    Abstract: The combination of adoptive cell therapy with CCR2 positive (CCR2+) hematopoietic stem cell transplantation increases T cell activation and survival.
    Type: Grant
    Filed: December 21, 2017
    Date of Patent: October 11, 2022
    Assignee: University of Florida Research Foundation, Incorporated
    Inventors: Duane Mitchell, Catherine Flores
  • Patent number: 11458156
    Abstract: This invention relates generally to pharmaceutical compositions and preparations of circular polyribonucleotides and uses thereof.
    Type: Grant
    Filed: September 22, 2021
    Date of Patent: October 4, 2022
    Assignee: Flagship Pioneering Innovations VI, LLC
    Inventors: Alexandra Sophie De Boer, Avak Kahvejian, Nicholas McCartney Plugis, Erica Gabrielle Weinstein, Sebastian Trousil, Morag Helen Stewart, Ki Young Paek, Catherine Cifuentes-Rojas
  • Patent number: 11458191
    Abstract: The present disclosure provides compositions and methods for targeting a Ras antigen to, for example, treat or prevent cancer. Disclosed embodiments include binding proteins, such as a T cell receptor or a chimeric antigen receptor, that bind to a Ras antigen:HLA complex. Polynucleotides encoding such binding protein can introduced into a host cell, such as a T cell, and the cell can be used in immunotherapy for treating various cancers. Also provided are immunogenic polypeptides that can be useful to, for example, induce an immune response against a mutated Ras or to identify a binding protein that binds to a Ras antigen.
    Type: Grant
    Filed: December 8, 2021
    Date of Patent: October 4, 2022
    Assignee: FRED HUTCHINSON CANCER CENTER
    Inventors: Rachel Perret, Philip D. Greenberg, Thomas M. Schmitt, Aude G. Chapuis, Ingunn M. Stromnes, Tijana Martinov
  • Patent number: 11459372
    Abstract: The present invention relates to, inter alia, an engineered cell (e.g., iPSC, IPS-derived NK, or NK cell) comprising a disrupted B2M gene and an inserted polynucleotide encoding one or more of SERPINB9, a fusion of IL15 and IL15R?, and/or HLA-E. The engineered cell can further comprise a disrupted CIITA gene and an inserted polynucleotide encoding a CAR, wherein the CAR can be an anti-BCMA CAR or an anti-CD30 CAR. The engineered cell may further comprise a disrupted ADAM17 gene, a disrupted FAS gene, a disrupted CISH gene, and/or a disrupted REGNASE-1 gene. Methods for producing the engineered cells are also provided, and therapeutic uses of the engineered cells are also described. Guide RNA sequences targeting described target sequences are also described.
    Type: Grant
    Filed: November 30, 2021
    Date of Patent: October 4, 2022
    Assignee: CRISPR THERAPEUTICS AG
    Inventors: Valentin Sluch, Alireza Rezania, Jason Sagert
  • Patent number: 11446345
    Abstract: The present disclosure provides therapeutic agents and uses thereof for drugs for treatment of tumors and/or cancers. The active ingredients of the therapeutic agents comprise an oncolytic virus that selectively replicate in tumor cells and comprise NK cells.
    Type: Grant
    Filed: January 3, 2018
    Date of Patent: September 20, 2022
    Assignee: HANGZHOU CONVERD CO., LTD.
    Inventors: Fang Hu, Lin Chen, Ronghua Zhao
  • Patent number: 11419894
    Abstract: This invention is directed to the treatment of cancers, e.g., inflammatory breast cancer, with NK (natural killer) cells wherein the cells are modified ex vivo such that their ability to overcome the chemorepellant effect of a tumor is enhanced. The cells may be genetically modified ex vivo and/or modified by contacting the cells ex vivo with an anti-chemorepellant agent. This invention also provides ex vivo modified NK cells, which are modified such that they express no or substantially no CXCR4 on their cell surface, or express CXCR7, or express a chimeric antigen receptor, or combinations thereof. The invention also relates to methods for treating a patient having a tumor, e.g., inflammatory breast cancer, by administering the modified NK cells, with or without treatment with other conventional anticancer treatments, e.g., chemotherapy, radiotherapy, viral therapies, hormonal therapies, as well as other immunotherapies and anti-chemorepellant therapies.
    Type: Grant
    Filed: September 15, 2017
    Date of Patent: August 23, 2022
    Assignee: The General Hospital Corporation
    Inventors: Mark C. Poznansky, Patrick Reeves
  • Patent number: 11421010
    Abstract: Provided herein are polypeptides comprising membrane-anchored IL-12. Also provided herein are T cells expressing the membrane-anchored IL-12. Further, methods of treating cancer comprising administering T cells expressing membrane-anchored IL-12 are provided herein. Also provided are combination treatments comprising T cells expressing membrane-anchored IL-12 and T cell chemoattractant-inducing chemokines. In addition, methods are provided for activating T cells to express NKG2D and methods of their use in the treatment of cancer.
    Type: Grant
    Filed: October 6, 2017
    Date of Patent: August 23, 2022
    Assignee: Board of Regents, The University of Texas System
    Inventors: Shulin Li, Jiemiao Hu, Xueqing Xia
  • Patent number: 11413315
    Abstract: Provided are methods and compositions for treating cancer with a combination of neural stem cells (NSCs) and an oncolytic virus or a combination of oncolytic virotherapy and immune modulation. The method entails administrating to a subject a pharmaceutical composition comprising a combination of NSCs and an oncolytic virus, and/or NSCs packaged with one or more immunomodulatory viruses expressing one or more immunity checkpoint inhibitors, including adaptive immunity checkpoint inhibitors and innate immunity checkpoint inhibitors. The immunity checkpoint inhibitors include shRNAs against the immunity checkpoint proteins. The cancer includes but is not limited to primary, recurrent, and metastatic brain cancer, breast cancer, head and neck cancer, bladder cancer, ovarian cancer, uterine cancer, prostate cancer, skin cancer, lung cancer, and colorectal cancer.
    Type: Grant
    Filed: April 29, 2019
    Date of Patent: August 16, 2022
    Assignee: CITY OF HOPE
    Inventors: Alexandra Jaqueline Annala, Karen Aboody, Jennifer Covello, Rachael Mooney
  • Patent number: 11413338
    Abstract: Disclosed herein are methods and compositions for treating cancer by eliciting an immune response by administering dendritic cells expressing heterologous proteins. In some embodiments, a dendritic cell comprises one or more heterologous nucleic acid molecules encoding for CD40L and CXCL13. In some embodiments, the dendritic cell further comprises a heterologous nucleic acid molecule encoding for CD93. In yet additional embodiments, the dendritic cells expressing heterologous proteins are activated.
    Type: Grant
    Filed: July 15, 2019
    Date of Patent: August 16, 2022
    Assignee: ENOCHIAN BIOPHARMA, INC.
    Inventor: Serhat Gumrukcu
  • Patent number: 11413310
    Abstract: Provided are adoptive cell therapy methods involving the administration of doses of cells for treating disease and conditions, including certain B cell malignancies. The cells generally express recombinant receptors such as chimeric antigen receptors (CARs). In some embodiments, the methods are for treating subjects with non-Hodgkin lymphoma (NHL). In some embodiments, the methods are for treating subjects with relapsed or refractory NHL. Also provided are articles of manufacture and prophylactic treatments in connection with adoptive therapy methods.
    Type: Grant
    Filed: June 1, 2018
    Date of Patent: August 16, 2022
    Assignee: Juno Therapeutics, Inc.
    Inventors: Tina Albertson, Brian Christin, Jacob Randolph Garcia, Christopher Glen Ramsborg, Claire L. Sutherland, Clinton Weber, Rachel K. Yost, Mark J. Gilbert, He Li
  • Patent number: 11399522
    Abstract: The invention discloses methods for the generation of chimaeric human-non-human antibodies and chimaeric antibody chains, antibodies and antibody chains so produced, and derivatives thereof including fully humanised antibodies; compositions comprising said antibodies, antibody chains and derivatives, as well as cells, non-human mammals and vectors, suitable for use in said methods.
    Type: Grant
    Filed: February 19, 2021
    Date of Patent: August 2, 2022
    Assignee: Kymab Limited
    Inventors: E-Chiang Lee, Jasper Clube, Allan Bradley
  • Patent number: 11389484
    Abstract: Compositions and methods of promoting wound healing in a human by administering to the human mesenchymal stem cells in an effective amount.
    Type: Grant
    Filed: December 10, 2018
    Date of Patent: July 19, 2022
    Assignee: Mesoblast International Sárl
    Inventors: Sudeepta Aggarwal, Mark F. Pittenger, Timothy Varney
  • Patent number: 11389485
    Abstract: Genetically engineered hematopoietic cells such as hematopoietic stem cells having one or more genetically edited genes of lineage-specific cell-surface proteins and therapeutic uses thereof, either alone or in combination with immune therapy that targets the lineage-specific cell-surface proteins.
    Type: Grant
    Filed: August 28, 2019
    Date of Patent: July 19, 2022
    Assignee: VOR BIOPHARMA INC.
    Inventors: Joseph Bolen, Aleksandar Filip Radovic-Moreno, John Lydeard
  • Patent number: 11382954
    Abstract: The present disclosure provides compositions and methods for targeting a Ras antigen to, for example, treat or prevent cancer. Disclosed embodiments include binding proteins, such as a T cell receptor or a chimeric antigen receptor, that bind to a Ras antigen:HLA complex. Polynucleotides encoding such binding protein can introduced into a host cell, such as a T cell, and the cell can be used in immunotherapy for treating various cancers. Also provided are immunogenic polypeptides that can be useful to, for example, induce an immune response against a mutated Ras or to identify a binding protein that binds to a Ras antigen.
    Type: Grant
    Filed: August 20, 2021
    Date of Patent: July 12, 2022
    Assignee: FRED HUTCHINSON CANCER CENTER
    Inventors: Rachel Perret, Philip D. Greenberg, Thomas M. Schmitt, Aude G. Chapuis, Ingunn M. Stromnes, Tijana Martinov